RedHawk Holdings' wholly-owned subsidiary, RedHawk Pharma, has been in discussions to potentially acquire certain cannabis assets including licenses to grow, manufacture and sell in the State of Oklahoma, with an anticipated initial focus on "craft" cultivation and distribution of product.
The Company anticipates a short but comprehensive due diligence period. A closing, if any, is expected to occur before December 31, 2020 and is contingent upon, among other things, approval by RedHawk's board of directors, the negotiation, acceptance and execution of a final definitive purchase agreement, acceptance and approval by the board of directors and the shareholders of the seller, satisfactory completion of legal and financial due diligence, RedHawk obtaining the required amount of acquisition financing, and the obtainment of all necessary consents and approvals of any third parties.
Accordingly, RedHawk cannot provide any assurance that a definitive agreement will be reached on acceptable terms or at all, that due diligence will be satisfactory, that the required acquisition financing will be obtained by RedHawk on acceptable terms or at all, or that the acquisition will ultimately be completed in any particular time frame or at all.
For more information:
RedHawk Holdings
100 Petroleum Drive, Suite 200, Lafayette, Louisiana 70508
(337) 269-5933
redhawkholdingscorp.com